# US 8,278,301 B2 · 2-alkylbenzoxazole carboxamides as 5HT3 modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,301 B2
- Document ID: US8278301B2
- Status: Granted
- Kind: B2
- Application number: 12/466,809
- Filed: 2009-05-15
- Published: 2009-09-10
- Granted: 2012-10-02
- Earliest claimed: 2006-08-07
- Assignees: Albany Molecular Research, Inc.
- Inventors: David D. Manning; Zhicai Yang
- Web page: https://patentgrep.com/patent/US8278301B2

## CPC

- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/18: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.

## Claims

### Claim 1

A method of treating irritable bowel syndrome, emesis, or post-operative nausea or vomiting, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula
wherein
R1, R2 and R3 are independently selected from the group consisting of hydrogen, halogen, amino, alkylamino, dialkylamino, acylamino, morpholinyl, —O-loweralkyl, hydroxy, loweralkyl, fluoroloweralkyl, —O-lowerfluoroalkyl, methylenedioxy, ethylenedioxy, alkoxy-loweralkyl and hydroxyloweralkyl;
R4 is a residue selected from the group consisting of:
(i) a saturated nitrogen heterocycle or methyl-substituted saturated nitrogen heterocycle, in which said nitrogen is tertiary, said heterocycle containing at least one 5 or 6-membered ring; and
(ii) an imidazolylalkyl residue wherein the imidazole of said imidazolylalkyl is optionally substituted with up to three groups chosen from halogen, (C1-C4)alkyl, substituted (C1-C4)alkyl and NH2; and
R10 is selected from the group consisting of
(i) hydrogen;
(ii) (C1-C10)alkyl;
(iii) substituted (C1-C10)alkyl;
(iv) saturated C-attached heterocyclyl; and
(v) substituted, saturated C-attached heterocyclyl.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said disorder is irritable bowel syndrome.

### Claim 3 (depends on 1)

A method according to claim 1 for treating emesis.

### Claim 4 (depends on 1)

A method according to claim 1 for treating post-operative nausea or vomiting.
